What's Wrong With Topical Diclofenac? With Dr. Raimar Loebenberg | Cherry Live!

We appreciate the importance of technological breakthroughs in advancing patient care at Cherry Health. When we heard about the next-generation nanotechnology base RS Therapeutics had developed for prescription delivery methods of compounding topical anti-inflammatories we needed to learn more!

‍

About the Event

Introducing Dr. Raimar Loebenberg founder of FoamaDerm who was looking for an answer to the question: “Why do doctors prescribe high concentrations of diclofenac in different bases”? He noticed concentrations as high as 20% of diclofenac are prescribed in different bases. As trained pharmacists and drug delivery experts, they saw that the science did not match up with the prescribing pattern. If a drug is released from its base and penetrates through the skin it can unfold its pharmacological effect locally. However, the total drug amount administered on one joint of a 20% compounded topical preparation already exceeds the recommended total daily dose. Serious side effects were reported for the commercial formulation containing 1% drug. However, patients were not getting any real pain relief from the higher concentrations either.

‍

Dr. Loebenberg thought there must be a better way. Through the development of a water-based nanotechnology foam which enhances drug release and ultimately skin penetration significantly was developed and now only 2% diclofenac could be administered to patients with joint pain. This new compounding foam base is now available under the trademark of FoamaDerm.

Avoid potential side effects and prescribe only what you need, with this optimized delivery method.

‍